vs
Side-by-side financial comparison of CrowdStrike (CRWD) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 1.9× CrowdStrike). Zoetis runs the higher net margin — 25.3% vs -2.8%, a 28.0% gap on every dollar of revenue. On growth, CrowdStrike posted the faster year-over-year revenue change (22.2% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $314.1M). Over the past eight quarters, CrowdStrike's revenue compounded faster (20.8% CAGR vs 4.4%).
CrowdStrike Holdings, Inc. is an American cybersecurity technology company based in Austin, Texas. It provides endpoint security, threat intelligence, and cyberattack response services.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CRWD vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $-34.0M | $603.0M |
| Gross Margin | 75.1% | 70.2% |
| Operating Margin | -5.6% | 31.9% |
| Net Margin | -2.8% | 25.3% |
| Revenue YoY | 22.2% | 3.0% |
| Net Profit YoY | -102.1% | 3.8% |
| EPS (diluted) | $-0.14 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.1B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.0B | $2.3B | ||
| Q3 24 | $963.9M | $2.4B | ||
| Q2 24 | $921.0M | $2.4B | ||
| Q1 24 | $845.3M | $2.2B |
| Q4 25 | $-34.0M | $603.0M | ||
| Q3 25 | $-77.7M | $721.0M | ||
| Q2 25 | $-110.2M | $718.0M | ||
| Q1 25 | $-92.3M | $631.0M | ||
| Q4 24 | $-16.8M | $581.0M | ||
| Q3 24 | $47.0M | $682.0M | ||
| Q2 24 | $42.8M | $624.0M | ||
| Q1 24 | $53.7M | $599.0M |
| Q4 25 | 75.1% | 70.2% | ||
| Q3 25 | 73.5% | 71.5% | ||
| Q2 25 | 73.8% | 73.6% | ||
| Q1 25 | 74.1% | 72.0% | ||
| Q4 24 | 74.7% | 69.5% | ||
| Q3 24 | 75.4% | 70.6% | ||
| Q2 24 | 75.6% | 71.7% | ||
| Q1 24 | 75.3% | 70.6% |
| Q4 25 | -5.6% | 31.9% | ||
| Q3 25 | -9.7% | 37.0% | ||
| Q2 25 | -11.3% | 36.7% | ||
| Q1 25 | -8.1% | 36.5% | ||
| Q4 24 | -5.5% | 31.6% | ||
| Q3 24 | 1.4% | 36.6% | ||
| Q2 24 | 0.8% | 33.0% | ||
| Q1 24 | 3.5% | 34.1% |
| Q4 25 | -2.8% | 25.3% | ||
| Q3 25 | -6.6% | 30.0% | ||
| Q2 25 | -10.0% | 29.2% | ||
| Q1 25 | -8.7% | 28.4% | ||
| Q4 24 | -1.7% | 25.1% | ||
| Q3 24 | 4.9% | 28.6% | ||
| Q2 24 | 4.6% | 26.4% | ||
| Q1 24 | 6.4% | 27.4% |
| Q4 25 | $-0.14 | $1.37 | ||
| Q3 25 | $-0.31 | $1.63 | ||
| Q2 25 | $-0.44 | $1.61 | ||
| Q1 25 | $-0.37 | $1.41 | ||
| Q4 24 | $-0.07 | $1.29 | ||
| Q3 24 | $0.19 | $1.50 | ||
| Q2 24 | $0.17 | $1.37 | ||
| Q1 24 | $0.23 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.8B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.0B | $3.3B |
| Total Assets | $10.0B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.8B | — | ||
| Q3 25 | $5.0B | $2.1B | ||
| Q2 25 | $4.6B | $1.4B | ||
| Q1 25 | $4.3B | $1.7B | ||
| Q4 24 | $4.3B | $2.0B | ||
| Q3 24 | $4.0B | $1.7B | ||
| Q2 24 | $3.7B | $1.6B | ||
| Q1 24 | $3.5B | $2.0B |
| Q4 25 | $4.0B | $3.3B | ||
| Q3 25 | $3.8B | $5.4B | ||
| Q2 25 | $3.5B | $5.0B | ||
| Q1 25 | $3.3B | $4.7B | ||
| Q4 24 | $3.1B | $4.8B | ||
| Q3 24 | $2.9B | $5.2B | ||
| Q2 24 | $2.5B | $5.0B | ||
| Q1 24 | $2.3B | $5.1B |
| Q4 25 | $10.0B | $15.5B | ||
| Q3 25 | $9.3B | $15.2B | ||
| Q2 25 | $8.7B | $14.5B | ||
| Q1 25 | $8.7B | $14.1B | ||
| Q4 24 | $7.8B | $14.2B | ||
| Q3 24 | $7.2B | $14.4B | ||
| Q2 24 | $6.8B | $14.2B | ||
| Q1 24 | $6.6B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $397.5M | $893.0M |
| Free Cash FlowOCF − Capex | $314.1M | $732.0M |
| FCF MarginFCF / Revenue | 25.5% | 30.7% |
| Capex IntensityCapex / Revenue | 6.8% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $397.5M | $893.0M | ||
| Q3 25 | $332.8M | $938.0M | ||
| Q2 25 | $384.1M | $486.0M | ||
| Q1 25 | $345.7M | $587.0M | ||
| Q4 24 | $326.1M | $905.0M | ||
| Q3 24 | $326.6M | $951.0M | ||
| Q2 24 | $383.2M | $502.0M | ||
| Q1 24 | $347.0M | $595.0M |
| Q4 25 | $314.1M | $732.0M | ||
| Q3 25 | $302.3M | $805.0M | ||
| Q2 25 | $298.4M | $308.0M | ||
| Q1 25 | $258.5M | $438.0M | ||
| Q4 24 | $247.4M | $689.0M | ||
| Q3 24 | $287.4M | $784.0M | ||
| Q2 24 | $333.5M | $370.0M | ||
| Q1 24 | $294.4M | $455.0M |
| Q4 25 | 25.5% | 30.7% | ||
| Q3 25 | 25.9% | 33.5% | ||
| Q2 25 | 27.0% | 12.5% | ||
| Q1 25 | 24.4% | 19.7% | ||
| Q4 24 | 24.5% | 29.7% | ||
| Q3 24 | 29.8% | 32.8% | ||
| Q2 24 | 36.2% | 15.7% | ||
| Q1 24 | 34.8% | 20.8% |
| Q4 25 | 6.8% | 6.7% | ||
| Q3 25 | 2.6% | 5.5% | ||
| Q2 25 | 7.8% | 7.2% | ||
| Q1 25 | 8.2% | 6.7% | ||
| Q4 24 | 7.8% | 9.3% | ||
| Q3 24 | 4.1% | 7.0% | ||
| Q2 24 | 5.4% | 5.6% | ||
| Q1 24 | 6.2% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 6.95× | 1.39× | ||
| Q2 24 | 8.95× | 0.80× | ||
| Q1 24 | 6.46× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRWD
| Subscription And Circulation | $1.2B | 95% |
| Professional Services | $65.5M | 5% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
